Correspondence to: Jerry W. Shay, Ph.D., Department of Cell Biology and Neuroscience, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75235-9039 (e-mail: Shay{at}UTSW.SWMED.EDU).
Normal human cells undergo an irreversible growth arrest after a limited number of cell divisions (1,2). In contrast, a hallmark of most cancer cells is their ability to divide an unlimited number of times. Lately, the importance of counteracting the limitations of normal cell growth as a cellular requirement for cancer progression has become appreciated (3-5). There is evidence for a genetic basis of cellular aging. Thus, somatic cell hybrids between immortal cancer cells and normal cells are mortal, demonstrating that cellular aging/senescence is dominant over immortality (6). These findings have been pursued in an attempt to identify specific genes regulating these processes. Microcell-mediated chromosome transfer has provided mounting evidence that there are several senescence-specific genetic pathways (7). In some instances, the introduction of specific chromosomes or genes into proliferating cells results in a rapid growth arrest, suggesting that a senescence-like stress response may quickly induce cell cycle checkpoints. In other instances, there is a significant delay after chromosome transfer until the growth arrest. Recent progress in understanding the basis for this latter observation is the subject of this editorial.
Reduction of Telomeres and Cellular Growth Arrest
The limited proliferative capacity of normal cells is now thought to be controlled by a generational clock that resides at the chromosome ends, the telomeres. The hexameric sequence, TTAGGG, is repeated several thousand times and comprises what is known as telomeric DNA (8). Due to the cell's inability to complete the replication of linear DNA [end replication problem (9)], some telomeric DNA is lost with each cell division. Telomeres thus provide a buffer of expendable, noncoding DNA to accommodate the end replication problem (10). Telomeres protect chromosome ends from degradation and recombination (11) and also promote correct mitotic separation of sister chromatids (12). In addition, telomeres serve as a platform for telomere binding proteins (13). When a critically shortened telomere length is reached, the senescence program is initiated, perhaps via a DNA damage checkpoint pathway (14). Indeed, there is increasing evidence that the sequential shortening of telomeric DNA may be an important molecular timing mechanism. Correlative evidence in support of this includes the following: 1) Telomeres are shorter in somatic tissues from older individuals when compared with younger individuals (15); 2) telomeres are shorter in somatic (body) tissues than comparable germline (reproductive) cells (16); 3) normal cells generally have longer telomeres than those in tumor cells obtained from the same individual (17); 4) children born with certain early aging syndromes have shorter telomeres than age-matched control subjects (18); and 5) telomeres in normal cells from young individuals progressively shorten when grown in cell culture (19).
Telomerase: a Cellular Reverse Transcriptase That Bypasses Telomere-Based Cell Growth Limitations
At birth, telomeres in human cells consist of about 15 000 base pairs of repeated TTAGGG DNA sequences (17). Every time a cell divides, it loses 25-200 DNA base pairs from the telomere ends (18,19). Once this pruning has occurred about 100 times, a cell undergoes senescence and does not continue dividing. Reproductive tissues must have a mechanism to compensate for the progressive telomere erosion, otherwise the species would soon be lost. Nature's solution for germline cells is telomere terminal transferase (telomerase), a ribonucleoprotein reverse transcriptase enzyme (20-22). Telomerase uses its RNA component containing an internal template complementary to the telomeric TTAGGG repeats to bind to telomeres. Its catalytic protein component synthesizes telomeric DNA directly onto the ends of chromosomes by the process of reverse transcription of the RNA template (20-26). Telomerase is present in most fetal tissues, normal adult male reproductive cells, inflammatory cells, proliferative cells of renewal tissues, and in most tumor cells (27-31).
Overall, the telomere/telomerase hypothesis of aging and cancer can be summarized as follows: 1) Progressive telomere loss in all somatic cells including stem cells of renewal tissues is normal and is the "clock" or timing mechanism that regulates cellular senescence (32,33); 2) cellular senescence occurs when only a single telomere or perhaps a few telomeres shorten to a critical length; 3) telomerase is repressed in most somatic tissues, and change(s) in the normal telomerase repression pathway cause the enzyme to increase in activity or reactivate; and 4) either telomerase activity or another mechanism to maintain telomere stability in cancer cells is a hallmark of all immortalized cancer cell populations. During the past 3 years, more than 500 papers have been published on the topic of telomerase. These have almost universally shown that telomerase is detected in primary tumors but not in adjacent cleared margins (28-31). Importantly, while there is a strong association between the presence of telomerase and cancer, this does not indicate that telomerase is either an oncogene or that it causes cancer (34).
Inhibiting Telomerase as a Therapy for Treating Cancer
Because telomerase activity is detected in almost all advanced tumors, it is hoped that scientists may be able to develop a therapy that inhibits telomerase activity and interferes with the growth of many types of cancer (35). Following conventional treatments (surgery, radiotherapy, and chemotherapy), antitelomerase agents would most likely be given to limit the proliferative capacity of the rare surviving tumor cells in the hope that this would prevent cancer recurrence. In addition, telomerase inhibitors could also be used as chemopreventive agents in high cancer-susceptibility individuals or in early stage cancer to prevent overgrowth of metastatic cells.
One important consideration with this proposed treatment regimen is the
prolonged time potentially required for a telomerase inhibitor to be
effective (Fig. 1). Since the mode of action of
telomerase inhibitors may require further telomeric shortening of
cancer cells before inhibition of cell proliferation, there may be a
significant delay in efficacy. The combinatorial use of telomerase
inhibitors with other cancer therapeutic agents may more effectively
achieve complete cancer remissions.
|
Evidence for a Chromosome 3 Telomerase Repressor
Introduction of a normal chromosome 3, but not chromosome 7 or 11, into a renal cell carcinoma cell line (RCC23) results in telomerase repression and progressive telomere shortening. After 23-43 population doublings, there is cessation of cell growth (37). Furthermore, the inhibition of cell growth is accompanied by expression of senescence-activated ß-galactosidase (38). Importantly, the reduction of telomerase activity is accompanied by a decrease in the abundance of messenger RNA encoding the catalytic protein subunit of telomerase (hTERT). Thus, the telomerase repressor on chromosome 3 may act either directly or indirectly as a transcriptional repressor of hTERT. This not only confirms that hTERT is the rate-limiting determinant of telomerase activity but also provides a direct link between telomerase repression and cellular senescence.
In this issue of the Journal, Cuthbert et al. (39) confirm the importance of a telomerase repressor on chromosome 3. In this study, introduction of a normal human chromosome 3 but not chromosome 8, 12, or 20 into a breast carcinoma cell line (21NT) resulted in telomerase repression followed by permanent growth arrest after 10-18 population doublings. Since the 21NT cells have telomeres that are about 3 kilobases (kb) and the RCC23 have about 6 kb of telomeres, the time of delay until growth arrest is consistent with a progressive telomere shortening, senescence-based mechanism.
There has been additional support for the presence of a telomerase repressor on chromosome 3. For example, Yashima et al. (40) showed that loss of heterozgosity at chromosome 3p occurs very early in the pathogenesis of non-small-cell lung cancer and that this coincides with the detection of telomerase activity in early preneoplastic lesions. Similarly, Mehle et al. (41) demonstrated loss of heterozygosity at 3p that is associated with telomerase activity in renal cell carcinoma. Vieten et al. (42) studying immortalization of uroepithelial cells and Steenbergen et al. (43) examining immortalization of keratinocytes also showed frequent losses of regions of 3p. The search for the putative telomerase repressor has been narrowed to the following regions: Cuthbert et al. (39) 3p12-21.1 and 3p21.3-p22; Vieten et al. (42) 3p13-14.2; Tanaka et al. (44) 3p14.2-p21.1; and Mehle et al. (41) 3p14.2-3p21.2 and 3p24.1-3p24.3. Efforts to map the location of the 3p telomerase repressor more precisely are continuing, with the hope that the isolation of the specific gene involved may soon be obtained.
The link between shortening of telomeres and cellular aging and that telomeres are stably maintained in cancer cells has prompted intense investigations into the pathways connecting cellular aging and cancer (45). The medical community is excited by the possibilities that manipulating telomere length could change the rate of cellular senescence and affect the degenerative diseases of aging or that inhibition of telomerase could provide a novel approach to cancer therapeutics. In summary, telomerase may be important in cancer diagnostics (46,47), as a target for cancer therapy (35,47), and in the treatment of age-related disease (32,34). The challenge is to find out how to make our cancer cells age and stop dividing and our aging but healthy cells continue to divide. Telomerase will likely have many important applications in the future of medicine and cell engineering.
NOTES
The author holds stock in and is currently conducting research sponsored in part by Geron Corp., Menlo Park, CA.
The author is an Ellison Medical Foundation Senior Scholar. Supported in part by Public Health Service grants CA70907, CA71613, and CN85044-63 (National Cancer Institute) and AG07992 (National Institute on Aging), National Institutes of Health, Department of Health and Human Services.
REFERENCES
1 Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614-36.
2 Campisi J. The biology of replicative senescence. Eur J Cancer 1997;33:703-9.[Medline]
3 Sager R. Senescence as a mode of tumor suppression. Environ Health Perspect 1991;93:59-62.[Medline]
4 Shay JW, Wright WE, Werbin H. Defining the molecular mechanisms of human cell immortalization. Biochim Biophys Acta 1991;1072:1-7.[Medline]
5
Sedivy JM. Can ends justify the means?: telomeres and the
mechanisms of replicative senescence and immortalization in mammalian cells. Proc Natl
Acad Sci U S A 1998;95:9078-81.
6 Norwood TH, Pendergrass WR, Sprague CA, Martin GM. Dominance of the senescent phenotype in heterokaryons between replicative and post-replicative human fibroblast-like cells. Proc Natl Acad Sci U S A 1974;71:2231-5.[Abstract]
7 Oshimura M, Barrett JC. Mutiple pathways to cellular senescence: role of telomerase repressors. Eur J Cancer 1997;33:710-5.[Medline]
8 Moyzis RK, Buckingham JM, Cram LS, Dani M, Daven LL, Jones MD, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 1988;85:6622-6.[Abstract]
9 Watson JD. Origin of concatemeric T7 DNA. Nat New Biol 1972;239:197-201.[Medline]
10 Olovnikov AM. Principle of marginotomy in template synthesis of polynucleotides. Dokl Akad Nauk SSSR 1971;201:1496-9.[Medline]
11 Zakian VA. Structure and function of telomeres. Annu Rev Genet 1989;23:579-604.[Medline]
12
Kirk KE, Harmon BP, Reichardt IK, Sedat JW, Blackburn EH,
et al. Block in anaphase chromosome separation caused by a telomerase template mutation. Science 1997;275:1478-81.
13 Chong L, van Steensel B, Broccoli D, Erdjument-Bromage H, Hanish J, Tempst P, et al. A human telomeric protein. Science 1995;270:1663-7.[Abstract]
14 Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991;256:271-82.[Medline]
15 Lindsey J, McGill NI, Lindsey LA, Green DK, Cooke HJ, et al. In vivo loss of telomeric repeats with age in humans. Mutat Res 1991;256:45-8.[Medline]
16 de Lange T, Shiue L, Myers RM, Cox DR, Naylor SL, Killery AM, et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990;10:518-27.[Medline]
17 Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC, et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990;346:866-8.[Medline]
18 Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 1992;89:10114-8.[Abstract]
19 Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-60.[Medline]
20 Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-13.[Medline]
21 Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989;337:331-7.[Medline]
22 Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989;59:521-9.[Medline]
23 Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995;269:1236-41.[Medline]
24
Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V,
Cech TR, et al. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997;276:561-7.
25
Nakamura TM, Morin GB, Chapman KB, Weinrich SL,
Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and
humans. Science 1997;277:955-9.
26 Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-95.[Medline]
27 Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996;18:173-79.[Medline]
28 Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.[Medline]
29 Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol 1996;8:66-71.[Medline]
30 Shay JW, Bacchetti S. A survey of telomerase in human cancer. Eur J Cancer 1997;33:787-91.[Medline]
31 Rhyu MS. Telomeres, telomerase, and immortality. J Natl Cancer Inst 1995;87:884-94.[Abstract]
32
Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin
GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-52.
33 Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998;8:279-82.[Medline]
34 Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson KS, et al. Lack of cancer-associated changes in human fibroblasts after immortalization with telomerase. Nat Genet. In press 1999.
35 Morin GB. Is telomerase a universal cancer target? [editorial]. J Natl Cancer Inst 1995;87:859-61.[Medline]
36 Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249-55.[Medline]
37 Ohmura H, Tahara H, Suzuki M, Ide T, Shimizu M, Yoshida MA, et al. Restoration of the cellular senescence program and repression of telomerase by human chromosome 3. Jpn J Cancer Res 1995;86:899-904.[Medline]
38 Horikawa I, Oshimura M, Barrett JC. Repression of the telomerase catalytic subunit by a gene on human chromosome 3 that induces cellular senescence. Mol Carcinog 1998;22:65-72.[Medline]
39
Cuthbert AP, Bond J, Trott DA, Gill S, Broni J, Marriott A, et
al. Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest
in human breast cancer cells. J Natl Cancer Inst 1999;91:37-45.
40 Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, et al. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinoma. Cancer Res 1997;57:2373-7.[Abstract]
41 Mehle C, Lindblom A, Ljungberg B, Stenling R, Roos G, et al. Loss of heterozygosity at chromosome 3p correlates with telomerase activity in renal cell carcinoma. Int J Cancer 1998;13:289-95.
42
Vieten L, Belair CD, Savelieva L, Julicher K, Brocker F,
Bardenheuer W, et al. Minimal deletion of 3p1214.2 associated with immortalization of
human uroepithelial cells. Genes Chromosomes Cancer 1998;21:39-48.[Medline]
43 Steenbergen RD, Walboomers JM, Meijer CJ, van der Raaij-Helmer EM, Parker JN, Chow LT, et al. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q, and/or 18q. Oncogene 1996;13:1249-57.[Medline]
44 Tanaka H, Shimuzu M, Horikawa I, Kugoh H, Yokota J, Barrett JC, et al. Evidence for a putative telomerase repressor in the 3p14.2-p21.1 region. Genes Chromosomes Cancer 1998;23:123-33.[Medline]
45 Shay JW. Aging and cancer: are telomeres and telomerase the connection? Mol Med Today 1995;1:378-84.[Medline]
46 Shay JW, Gazdar AF. Telomerase in the early detection of cancer. J Clin Pathol 1997;50:106-9.[Abstract]
47 Shay JW. Telomerase in cancer: diagnostic, prognostic, and therapeutic implications. Cancer J Sci Am 1998;4 Suppl 1:S26-34.[Medline]
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |